Journal Scans
Addition of Bevacizumab to Standard Chemoradiation For Locoregionally Advanced Nasopharyngeal Carcinoma (RTOG 0615): A Phase 2 Multi-Institutional Trial
Bevacizumab Plus Chemoradiation in Nasopharyngeal Carcinoma
NY Lee, Q Zhang, DG Pfister, KK Ang, et al
20111115
2011 Dec 15
Lancet Oncol
Addition of Bevacizumab to Standard Chemoradiation For Locoregionally Advanced Nasopharyngeal Carcinoma (RTOG 0615): A Phase 2 Multi-Institutional Trial
Lancet Oncol. 2011 Dec 15;[Epub Ahead of Print], NY Lee, Q Zhang, DG Pfister, KK Ang, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: We aimed to improve the outcomes for locoregionally advanced nasopharyngeal carcinoma by testing the feasibility and safety of the addition of bevacizumab to chemoradiotherapy.Methods: We enrolled patients older than 18 years with stage IIB-IVB nasopharyngeal carcinoma from 19 centres in North America and Hong Kong. Treatment consisted of three cycles of bevacizumab (15 mg/kg) and cisplatin (100 mg/m2) both given on days 1, 22, and 43 of radiation (70 Gy) with intensity-modulated radiation...
